CTLA4 and cancer: The concept that the CTLA-4 and PD-1 receptors might be utilised by cancer cells to avoid the immune system led to the development of monoclonal antibodies that could inhibit these receptors, with the hope that targeting them would lead to a more effective anti-tumour response from T lymphocytes.